Part:BBa_K5384001

Vglycin (Vg)

Vglycin contains six cysteine residues at sites 3,7,15,20,22 and 32 and forms three pairs of disulfide bonds, can resist the degradation of gastrointestinal protease, with oral hypoglycemic effect[1,2].

Figure 1: The three-dimensional structure of the Vglycin

Usage and Biology

The concrete biological functions of Vg have been proved by previous studies.The long-term administration of Vg has excellent hypoglycemic and lipid-lowering effect on mice.P37 has a hypoglycemic effect comparable to metformin on this graph. The other two figures are evidence of reduction of belly fat and liver fat. Moreover, previous studies also proved Vg can repaired the damage pancreas induced by streptozotocin. These are some experimental evidence.

Figure 2: Vglycin normalized fasting plasma glucose levels in HFD-fed C57BL/6J mice. On days 0, 35, 70, 105, 140, 175, fasting blood glucose of these mice was measured

Figure 3: H&E staining of the pancreatic sections.

Sequence and Features

Assembly Compatibility:

• 10
  COMPATIBLE WITH RFC[10]
• 12
  COMPATIBLE WITH RFC[12]
• 21
  COMPATIBLE WITH RFC[21]
• 23
  COMPATIBLE WITH RFC[23]
• 25
  COMPATIBLE WITH RFC[25]
• 1000
  COMPATIBLE WITH RFC[1000]

Application

Compared with traditional small-molecule chemical drugs, active peptide drugs P37 have small molecular weight, simple structure and no immunogenicity. The mechanism of action is clear and the side effects are low; Synthetic purity, easy synthesis and other unique advantages[3].It can resist the degradation of gastrointestinal proteases and has the effect of oral hypoglycemia.

Functional Parameters

function

This sequence codes for Vglycin, which is a peptide derived from leguminous plants. It contains 37 amino acids. It has six cysteine residues located at positions 3, 7, 15, 20, 22, and 32, forming three pairs of disulfide bonds within the molecule. It is resistant to degradation by gastrointestinal proteases and has the effect of lowering blood sugar when taken orally. Vg has excellent hypoglycemic effect on mice and can repair damaged pancreas.

References

[1]Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016).Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64(1), 73–84.

[2]Neuschwander-Tetri, B. A. (2017). Non-alcoholic fatty liver disease. BMC Med. 15(1), 45.Charlton, M. (2004). Nonalcoholic fatty liver disease: A review of current understandingand future impact. Clin gastroenterol hepatol. 2, 1048–1058.

[3]Vuppalanchi, R., & Chalasani, N. (2009). Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.Hepatology, 49, 306–317.